Literature DB >> 23348800

Cystatin C and neutrophil gelatinase-associated lipocalin: biomarkers for acute kidney injury after congenital heart surgery.

S Seitz1, M Rauh, M Gloeckler, R Cesnjevar, S Dittrich, A M Koch.   

Abstract

QUESTIONS UNDER STUDY: To evaluate the diagnostic value of serum Cystatin C and urine neutrophil gelatinase-associated lipocalin (NGAL) for the detection of acute kidney injury in patients undergoing congenital heart surgery.
METHODS: Serial samples of serum Cystatin C and urine NGAL were collected from 139 consecutive patients with congenital heart defects aged 3 days to 30 years after admission to the intensive care unit, 2 and 6 hours after the end of cardiopulmonary bypass. Biomarker levels were compared to perioperative data retrospectively. Acute kidney injury was defined according to the paediatric-modified RIFLE classification.
RESULTS: According to the paediatric-modified RIFLE criteria 53% of patients developed evidence of acute kidney injury. Serum Cystatin C concentrations were strongly correlated with severity of acute kidney injury. Optimal sensitivity of 80% and specificity of 66% for the prediction of acute kidney injury occurred at a cut-off value of 0.995 mg/l, 2 hours after the end of cardiopulmonary bypass. The 2 hour urine NGAL concentration was significantly correlated to the duration of cardiopulmonary bypass, time of aortic cross clamping, and serum lactate concentration. Moreover a significant correlation was found between urine NGAL and both length of hospital stay and mechanical ventilation.
CONCLUSIONS: In patients after congenital heart surgery, urine NGAL indicates the damaging force of cardiopulmonary bypass and serum Cystatin C is a valuable predictive biomarker for resulting acute kidney injury.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23348800     DOI: 10.4414/smw.2013.13744

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  6 in total

1.  Potential Role of Allopurinol in Preventing Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention: A Randomized Placebo-Controlled Trial.

Authors:  Zahra Ghelich Khan; Azita Hajhossein Talasaz; Hamidreza Pourhosseini; Kianoush Hosseini; Mohammad Javad Alemzadeh Ansari; Arash Jalali
Journal:  Clin Drug Investig       Date:  2017-09       Impact factor: 2.859

2.  Early detection of acute kidney injury after pediatric cardiac surgery.

Authors:  John Lynn Jefferies; Prasad Devarajan
Journal:  Prog Pediatr Cardiol       Date:  2016-06

3.  Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis.

Authors:  Miriam Brazzelli; Lorna Aucott; Magaly Aceves-Martins; Clare Robertson; Elisabet Jacobsen; Mari Imamura; Amudha Poobalan; Paul Manson; Graham Scotland; Callum Kaye; Simon Sawhney; Dwayne Boyers
Journal:  Health Technol Assess       Date:  2022-01       Impact factor: 4.106

4.  Umbilical neutrophil gelatinase-associated lipocalin level as an early predictor of acute kidney injury in neonates with hypoplastic left heart syndrome.

Authors:  Piotr Surmiak; Małgorzata Baumert; Małgorzata Fiala; Zofia Walencka; Andrzej Więcek
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

Review 5.  Biomarkers of acute kidney injury in pediatric cardiac surgery.

Authors:  Candice Torres de Melo Bezerra Cavalcante; Marcelo Borges Cavalcante; Klebia Magalhães Pereira Castello Branco; Titus Chan; Isabel Cristina Leite Maia; Ronald Guedes Pompeu; Andrea Consuelo de Oliveira Telles; Anna Karina Martins Brito; Alexandre Braga Libório
Journal:  Pediatr Nephrol       Date:  2021-05-25       Impact factor: 3.714

6.  Ulinastatin Protects against Acute Kidney Injury in Infant Piglets Model Undergoing Surgery on Hypothermic Low-Flow Cardiopulmonary Bypass.

Authors:  Xiaocou Wang; Qinghua Xue; Fuxia Yan; Jinping Liu; Shoujun Li; Shengshou Hu
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.